advanced search

Welcome: Guest

log in

Dermatology Alopecia (Hair Loss)

Publication Date March 2008
Publisher Life Science Analytics
Product Type Report
Pages 48
ISBN Number not applicable
Product Code LSA02332
Price

£800.00
approximately: $1,413 | €1,014

PDFBuy Now
PRINT £850 ($1,501 | €1,078)Buy Now
Order above formats by FAXOrder by FAX

Summary

Life Science Analytics', Central Nervous System Schizophrenia contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of allergy drugs by company and by stage as well as a summary of the latest news and developments in this area.

Scope of the report:

Each Life Science Analytics' Therapy Area Pipeline Report provides the user with real detail on drug pipelines, by company and by stage, for each specific therapy area. The latest news, by company, also ensures that each report is fresh and up-to-date.

In addition to new developments and disease specific pipeline projects, each report also contains extensive information in tabular format on a company's full product pipeline and products by phase of development with regard to the therapy area.

Full pipeline details, by stage, are provided and include detailed product descriptions, information on partnering activity plus clinical trial intelligence. Each Therapy Area Pipeline Report also provides detail on the top 20 companies with products in the early stage of development and the top 20 companies with products in the late stage of development. Finally, each report also provides a comparison with other major indications in the disease hub based on Marketed Products vs. Pipeline Products.

Key benefits

  • Understand a company's strategic position by accessing detailed independent intelligence on its product pipeline for specific therapy areas.
  • Keep track of your competitors and partners by better understanding their product pipeline.
  • Monitor a company's research effectiveness by determining pipeline depth and number of products in development by clinical phase for specific disease areas.
  • Maintain a critical competitive advantage.

Content

  • Recent Highlights and Changes
  • Upcoming Patent Expires by Therapy Area
    • Schizophrenia Pipeline Overview
      • % of Projects (by Phase of Development)
      • No. of Projects by Phase of Development
      • Marketed Products vs. Pipeline Products
    • Company Overview - Pipeline Projects
      • Company Overview - Pipeline Projects
      • Top Companies in late stage Schizophrenia Projects
      • ACADIA Pharmaceuticals Inc
      • Abbott Laboratories
      • BioLineRx, Ltd.
      • Barr Pharmaceuticals Inc
      • Eli Lilly & Co
      • Dainippon Sumitomo Pharma Co., Ltd.
      • Fabre-Kramer Pharmaceuticals, Inc.
      • Evotec AG
      • GlaxoSmithKline plc
      • Forest Laboratories Inc
      • Laboratorios Almirall, S.A.
      • Johnson & Johnson
      • Mylan, Inc.
      • Merck & Co Inc
      • Ranbaxy Laboratories Ltd.
      • Potomac Pharma, Inc.
      • Solvay S.A.
      • Schering-Plough Corp
      • Wyeth
      • Stem Cell Therapeutics Corp.
      • Top Companies in early stage Schizophrenia Projects
      • Addex Pharmaceuticals SA
      • Abbott Laboratories
      • AstraZeneca Plc
      • Argolyn Bioscience Inc.
      • GlaxoSmithKline plc
      • elbion NV
      • Johnson & Johnson
      • Intra-Cellular Therapies, Inc.
      • NeuroSearch A/S
      • Merck & Co Inc
      • Pfizer Inc
      • Oakwood Laboratories, L.L.C.
      • Roche Holdings Ltd
      • Pierre Fabre Medicament
      • Sanofi-Aventis
      • Rottapharm SpA
      • Taisho Pharmaceutical Co., Ltd.
      • Sigma-Tau S.p.A.
      • Wyeth
      • Targacept Inc
    • Pipeline Revenue
      • Pipeline Revenue
    • Full Pipeline View
      • Pre Clinical Pipeline View
      • Phase I Pipeline View
      • Phase II Pipeline View
      • Phase III Pipeline View
      • Pending Approval Pipeline View
      • Post Marketing Pipeline View
      • on the Market Pipeline View
      • Discovery/Development Pipeline View